Compass Therapeutics Inc (CMPX) USD0.0001
$0.01
(0.73%)
- Add to watchlist
- This stock can be held in a
$0.01
(0.73%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.01
(0.73%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.
Contact details
Important dates
General stock information
- Short code:
- CMPX
- ISIN:
- US20454B1044
- Market cap:
- $195.38 million
- Shares in issue:
- 137.59 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.